|
FOR US RESIDENTS ONLY
|
Chronic Myeloid Leukemia (Ph+ CML)
Treatment Reimbursement Support for
Patients
Helping to make Ph+ CML treatment available to more patients
The CML Alliance is committed to providing access to CML medications available from Novartis Oncology to those patients meeting financial eligibility requirements. In addition, we provide resources to facilitate the reimbursement process for physicians and their patients.
Through a variety of programs, including the Novartis Patient Assistance Program (PAP), Novartis Oncology Reimbursement Hotline, and the CML Access Program (CAP) we have made a firm commitment to ensuring patients get the CML treatments they need.
Novartis Oncology Reimbursement Hotline
Novartis Patient Assistance Program (PAP)
Novartis CML Access Program (CAP)
Novartis Oncology Reimbursement Hotline
1-800-282-7630 *
By calling 1-800-282-7630, providers and patients can receive assistance in resolving reimbursement issues and concerns.
The following are the support services provided through this hotline:
- Insurance Verification - The program verifies patients' medical benefits, helps determine insurance coverage, and clarifies co-payment obligations.
- Denials/appeals - The program assists providers in obtaining appropriate reimbursement.
- Coding/billing questions - Program staff can assist providers with questions regarding coding and billing.
- Alternative funding searches - Program staff can search for possible assistance for patients with insufficient or no drug coverage and refer to other sources of funding that may help alleviate or reduce costs.
Novartis Patient Assistance Program (PAP)
In 2007, Novartis Oncology was proud to provide $88 million of free product to over 9,000 patients in need in the U.S through the Novartis PAP. The program provides assistance to US residents meeting eligibility requirements.
Patient eligibility requirements:
- US residency
- Meets financial eligibility requirements
- No prescription drug coverage (public or private)
- Exception process exists for patients who cannot afford their Medicare Part D cost share
Program enrollment:
Patients must reapply/requalify annually
Phone the Novartis Oncology Reimbursement Hotline at:
1-800-282-7630*
Web site: www.pap.novartis.com
Novartis CML Access Program (CAP)
The CML Access Program (CAP) reflects the commitment of the CML Alliance and Novartis Oncology to patients by helping to provide therapy to CML patients who have insurance, but who cannot afford the cost-sharing obligations for medication. Patients enrolled in CAP pay for no more than 5% of their adjusted gross income for their Ph+ CML treatment.
Patient eligibility requirements:
- Applies to coverage of Novartis therapies for Ph+ CML
- Once a patient has spent 5% of his or her adjusted gross income for these medications, additional prescriptions will be provided for free for the remainder of the year
Program enrollment:
Patients must reapply/requalify annually
Phone the Novartis Oncology Reimbursement Hotline at:
1-800-282-7630*
Co-Pay Assistance
Financial assistance may be available from independent charitable foundations for eligible patients who are unable to afford their co-pay costs. Below is a list of foundations that may be able to provide financial support.
Healthwell Foundation
1-800-675-8416
http://www.healthwellfoundation.org
Patient Services, Inc
1-800-366-7741
http://www.uneedpsi.org
Patient Advocate Foundation
1-866-512-3861
http://www.copays.org
Patient Access Network Foundation
1-800-316-7263
http://www.patientaccessnetwork.org
National Organization for Rare Disorders (NORD)
1-800-999-6673
http://www.rarediseases.org
Chronic Disease Fund (CDF)
1-877-968-7233
http://www.cdfund.org
Disclaimer: *The Reimbursement Hotline and Novartis Pharmaceuticals Corporation do not guarantee success in obtaining reimbursement, nor do we submit appeals on behalf of providers or patients. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved by Reimbursement Hotline staff.
Use of this website is governed by the
Terms of Use
and
Privacy Statement
.
Copyright 2008 Novartis Pharmaceuticals Corporation. All Rights Reserved.
|